Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Official Title: A Phase 1B/2 Study of the Safety and Tolerability of Itacitinib (INCB039110) in Combination With Gemcitabine and Nab-Paclitaxel in Subjects With Advanced Solid Tumors

NCT01858883 is registered in ClinicalTrials.gov with Incyte Corporation as lead sponsor.

NCT NCT01858883
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01858883 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Official Title: A Phase 1B/2 Study of the Safety and Tolerability of Itacitinib (INCB039110) in Combination With Gemcitabine and Nab-Paclitaxel in Subjects With Advanced Solid Tumors
Lead sponsor
Incyte Corporation
Phase
Phase 1/2
Overall status
Completed
Start date
June 30, 2013
Completion date
March 31, 2016
Enrollment
55 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic cancer, solid tumors